# Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

Study · id `cardio:ct-nct05957887` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05957887](<https://clinicaltrials.gov/study/NCT05957887>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05957887

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05957887. Randomized; no masking; primary purpose treatment. Start 2022-04-15 (actual); primary completion 2025-03-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05957887, source copy `cardio:ctgov-nct05957887-2024-04-16`, retrieved 2026-10-26)
- Started: 2022-04-15 (actual) (ClinicalTrials.gov record NCT05957887, source copy `cardio:ctgov-nct05957887-2024-04-16`, retrieved 2026-10-26)
- Primary completion: 2025-03-15 (anticipated) (ClinicalTrials.gov record NCT05957887, source copy `cardio:ctgov-nct05957887-2024-04-16`, retrieved 2026-10-26)
- Completion: 2025-04-15 (anticipated) (ClinicalTrials.gov record NCT05957887, source copy `cardio:ctgov-nct05957887-2024-04-16`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05957887, source copy `cardio:ctgov-nct05957887-2024-04-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05957887-2024-04-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
- Condition: STEMI
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Mohamed Nabil Elkholy
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: c8563c58c07d51bdfae882b6fbdf4caeeee247ef9c823f3b1895b10e1b2be4a7
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
